The North America Infertility Drugs Market would witness market growth of 5.6% CAGR during the forecast period (2022-2028).
Medicaid's reimbursement of maternity and family planning services stands in contrast with its complete absence of coverage for fertility treatments. Medicaid supports the bulk of publicly funded family planning services as well as roughly half of the births in the U.S. As a consequence, even though numerous contraceptive and low-income services are often offered throughout pregnancy, there is limited access to help for low-income pregnancies. Only one state, New York, permits Medicaid to pay for fertility services in the United States as of January 2020. These are the main obstacles to market expansion.
Governments have launched a number of programs to help those who are struggling with infertility by offering insurance coverage for therapy. The Ministry of Health, Labor, and Welfare (MHLW), for instance, announced the payment under the national health insurance program in March 2022. By reducing the cost by 70% and increasing the number of prescriptions for medications, this program improves patients' access to care.
It is also anticipated that the availability of a broad range of medications for the treatment of infertility issues would benefit the industry. For instance, some of the fertility drugs on the market include Crinone (progesterone gel), Pregnyl (chorionic gonadotropin), Ovidrel (choriogonadotropin alfa), Menopur (Gonal-F), Follistim A (follitropin beta), Ganirelix Acetate Injection, Cetrotide (cetrorelix acetate), Clomid (clomiphene citrate), Bravelle (urofollitropin), and First-Progesterone.
One of the main factors influencing the development of the infertility medications market in the U.S. is the high concentration of market participants or manufacturer's presence, acquisitions, and partnerships among significant companies and an increase in the number of infertility and PCOS patients in the nation. These occurrences thus show that the market in the United States is expanding significantly. As a result of the aforementioned variables, the North American region expects the studied market to increase.
The US market dominated the North America Infertility Drugs Market by Country in 2021; thereby, achieving a market value of $1,312.5 million by 2028. The Canada market is experiencing a CAGR of 8% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 7% during (2022 - 2028).
Based on End User, the market is segmented into Women and Men. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Specialty & Retail Pharmacy, and Online Pharmacy. Based on Drug Class, the market is segmented into Gonadotropins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Dopamine Agonists, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Infertility Drugs Market is Predict to reach $4.8 Billion by 2028, at a CAGR of 6.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Bayer AG, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Ferring Holdings SA, Organon & Co. and Mankind Pharma Ltd.
By End User
By Distribution Channel
By Drug Class
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 